Reported Earnings • Aug 16
Second quarter 2026 earnings released: US$1.28 loss per share (vs US$345 loss in 2Q 2025) Second quarter 2026 results: US$1.28 loss per share (improved from US$345 loss in 2Q 2025). Net loss: US$2.87m (loss narrowed 26% from 2Q 2025). Announcement • Jul 30
Onconetix, Inc. announced that it expects to receive $780.2496 million in funding Onconetix, Inc. entered into a securities purchase agreement with an accredited investor (the “ PIPE Investor ”) pursuant to which the Company agreed to issue and sell to the PIPE Investor an aggregate of 37,812 shares of Series F convertible preferred stock, par value $0.00001 per share at an issue price of $800 for gross proceeds of $30,249,600 and the company also entered into a Common Stock Purchase Agreement relating to a committed equity facility (the “ ELOC Purchase Agreement ”) with an accredited investor pursuant to which, subject to the terms and conditions set forth therein, the Company has the right, but not the obligation, to direct the ELOC Investor, from time to time and at the Company’s sole discretion to issue common shares for gross proceeds of up to lesser of $750,000,000 on July 28, 2026. The company will raise total aggregate gross proceeds of $780,249,600. The preferred shares have a stated value of $1000 per share and are issued at a discount of 20%. The Series F Preferred Stock ranks junior to any Senior Preferred Stock, pari passu with the Company’s Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock, and senior to the Company’s Common Stock and other junior securities with respect to dividend rights and rights upon liquidation, dissolution and winding up of the Company. Holders of the Series F Preferred Stock are entitled to receive dividends when and as declared by the Company’s board of directors out of funds legally available therefor. Each holder may convert all or any portion of its Series F Preferred Stock into shares of the Company’s Common Stock at an initial conversion price of $0.9767 per share, subject to adjustment. The Company has the right, subject to the terms and conditions of the Certificate of Designations, to redeem all or a portion of the outstanding Series F Preferred Stock for cash. The common shares to be issued pursuant to ELOC is up to the lesser of 19.99% of the total number of shares of the Company’s Common Stock outstanding immediately prior to the execution of the ELOC Purchase Agreement, unless stockholder approval has been obtained or an exception under the applicable Nasdaq listing rules applies. In consideration for the ELOC Investor’s commitment under the ELOC Purchase Agreement, the Company agreed to pay a $30,000,000 commitment fee. The issuance and sale of the Series F Preferred Stock and the shares of Common Stock issuable upon conversion thereof have not been registered under the Securities Act of 1933, as amended (the “ Securities Act ”), or applicable state securities laws, in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated thereunder. The Company shall reimburse the lead Buyer a non-accountable amount of $75,000 for all costs and expenses incurred by it or its affiliates in connection with the offering. Announcement • May 19
Onconetix, Inc. Announces 1-For-10 Reverse Stock Split to Maintain Compliance with the Minimum Bid Price Requirement Onconetix, Inc. announced that its Board of Directors has approved a 1-for-10 reverse stock split of its outstanding shares of common stock, to be effective on May 21, 2026. On April 30, 2026, Onconetix held a special meeting of stockholders, at which the Company's stockholders approved a proposal to effect one or more reverse splits, at a ratio in the range of 1-for-2 to 1-for-10, at any time prior to the one-year anniversary date of the Special Meeting, with such ratio to be determined by the Board without further approval or authorization of the stockholders, provided that the Company shall not effect reverse stock splits that, in the aggregate, exceed 1-for-100. Since the receipt of such stockholder approval, the Company's Board of Directors has determined to fix a split ratio of 1-for-10 shares. The Company's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on May 21, 2026. Following the reverse stock split, the Company's common stock will continue to trade on The Nasdaq Capital Market under the symbol ONCO under the new CUSIP number 68237Q 401. The reverse stock split is intended to enable the Company to maintain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on The Nasdaq Capital Market. At the effective time of the reverse split, every 10 issued and outstanding shares of the Company's common stock will be converted automatically into one share of the Company's common stock without any change in the par value per share. No fractional shares will be issued in connection with the reverse stock split, and fractional shares resulting from the reverse stock split will be canceled with the holders thereof receiving cash compensation. The amount of compensation will be determined by multiplying the fractional share by the closing price per share of the Company's common stock on The Nasdaq Capital Market at the close of business on the trading day prior to the effective date of the reserve stock split, or May 21, 2026. The reverse split will have no effect on the number of authorized shares of the Company's common stock, and the ownership percentage of each stockholder will remain unchanged other than as a result of fractional shares. The reverse stock split will additionally apply to the Company's common stock issuable upon exercise or conversion of the Company's equity awards, convertible preferred stock and warrants, as well as the applicable exercise price. 
